Klin Farmakol Farm. 2012;26(4):194-197

Pantoprazole for parenteral use

Ivona Šimková1, Karel Urbánek2
1 II. interní klinika &ndash, gastroenterologická a hepatologická, LF UP a FN Olomouc
2 Ústav farmakologie, LF UP a FN Olomouc

Pantoprazole is one of the proton pump inhibitors, which is available in parenteral dosage form. It differs from other substances of this group

by the absence of clinically significant drug interactions. It can be used in all indications of PPI if parenteral administration is preferable.

Keywords: pantoprazole, proton pump inhibitors, parenteral administration, indications

Published: December 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šimková I, Urbánek K. Pantoprazole for parenteral use. Klin Farmakol Farm. 2012;26(4):194-197.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Garnett WR. History of acid suppression: focus on the hospital setting. Pharmacotherapy. 2003; 23 (10 Pt 2): 56S-60S. Go to original source... Go to PubMed...
    2. Shin JM, Munson K, Vagin O, Sachs G. The gastric HK-ATPase: structure, function, and inhibition. Pflugers Arch. 2009; 457(3): 609-622. Go to original source... Go to PubMed...
    3. Cheng HC, Sheu BS. Intravenous proton pump inhibitors for peptic ulcer bleeding: Clinical benefits and limits. J Gastrointest Endosc. 2011; 16; 3(3): 49-56. Go to original source... Go to PubMed...
    4. Martínek J, Lukáš M. Inhibitory protonové pumpy-up to date. Gastroent Hepatol 2011; 65(6): 331-342.
    5. Mathews S, Reid A, Tian C, Cai Q. An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease. Clin Exp Gastroenterol. 2010; 3: 11-16. Go to original source... Go to PubMed...
    6. Mayer O. Klinická farmakologie inhibitorů protonové pumpy se zaměřením na pantoprazol. Folia Gastroenterol Hepatol 2008; 6(3): 112-115.
    7. Blume H, Donath F, Warnke A, Schug BS. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. 2006; 29(9): 769-784. Go to original source... Go to PubMed...
    8. Kliem V, Bahlmann J, Hartmann M, Huber R, Lühmann R, Wurst W. Pharmacokinetics of pantoprazole in patients with end-stage renal failure. Nephrol Dial Transplant. 1998; 13(5): 1189-1193. Go to original source... Go to PubMed...
    9. Garrido Fernández S, Cumplido JA, Rábano A, Martínez D, Blanco C, Carrillo T. Allergy to proton pump inhibitors: diagnosis and assessment of cross-reactivity. J Investig Allergol Clin Immunol. 2008; 18(2): 140-141.
    10. Sierra F, Suarez M, Rey M, Vela MF. Systematic review: Proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther. 2007; 26(4): 545-553. Go to original source... Go to PubMed...
    11. Oh S. Proton pump inhibitors uncommon adverse effects. Aust Fam Physician. 2011; 40(9): 705-708. Go to PubMed...
    12. Ricketson J, Kimel G, Spence J, Weir R. Acute allergic interstitial nephritis after use of pantoprazole. CMAJ. 2009; 180(5): 535-538. Go to original source... Go to PubMed...
    13. Clark DW, Strandell J. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors? Eur J Clin Pharmacol. 2006; 62(6): 473-479. Go to original source... Go to PubMed...
    14. El-Nujumi A, Williams C, Ardill JE, Oien K, McColl KE. Eradicating Helicobacter pylori reduces hypergastrinaemia during long-term omeprazole treatment. Gut. 1998; 42(2): 159-165. Go to original source... Go to PubMed...
    15. Blume H, Donath F, Warnke A, Schug BS. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. 2006; 29(9): 769-784. Go to original source... Go to PubMed...
    16. Pang SH, Graham DY. A clinical guide to using intravenous proton-pump inhibitors in reflux and peptic ulcers. Therap Adv Gastroenterol. 2010; 3(1): 11-22. Go to original source... Go to PubMed...
    17. Andriulli A, Merla A, Bossa F, Gentile M, Biscaglia G, Caruso N. How evidence-based are current guidelines for managing patients with peptic ulcer bleeding? J Gastrointest Surg. 2010; 27; 2(1): 9-13. Go to original source... Go to PubMed...
    18. Armstrong D. Intravenous proton pump inhibitor therapy: a rationale for use. Rev Gastroenterol Disord. 2005; 5(Suppl 2): S18-30. Go to PubMed...
    19. Baker DE. Intravenous proton pump inhibitors. Rev Gastroenterol Disord. 2006; 6(1): 22-34. Go to PubMed...
    20. Wang J, Yang K, Ma B, Tian J, Liu Y, Bai Z, Jiang L, Sun S, Li J, Liu R, Hao X, He X. Intravenous pantoprazole as an adjuvant therapy following successful endoscopic treatment for peptic ulcer bleeding. Can J Gastroenterol. 2009; 23(4): 287-299. Go to original source... Go to PubMed...
    21. Liang CM, Lee JH, Kuo YH, et al. Intravenous Non-high-dose Pantoprazole is equally effective as High-dose Pantoprazole in Preventing Rebleeding among Low Risk Patients with a Bleeding Peptic Ulcer after Initial Endoscopic Hemostasis. BMC Gastroenterol. 2012; 12(1): 28. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.